StockNews.com assumed coverage on shares of GlycoMimetics (NASDAQ:GLYC – Free Report) in a research report released on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock.
Separately, TD Cowen lowered GlycoMimetics from a buy rating to a hold rating in a report on Friday, July 26th.
Read Our Latest Stock Report on GLYC
GlycoMimetics Price Performance
Insider Buying and Selling at GlycoMimetics
In other news, major shareholder Public Equities L.P. Invus sold 363,949 shares of the company’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $0.24, for a total value of $87,347.76. Following the transaction, the insider now directly owns 7,966,780 shares of the company’s stock, valued at approximately $1,912,027.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders have sold 911,859 shares of company stock worth $205,659. 8.70% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On GlycoMimetics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in GLYC. Vanguard Group Inc. grew its position in GlycoMimetics by 14.0% in the first quarter. Vanguard Group Inc. now owns 2,761,981 shares of the biotechnology company’s stock worth $8,286,000 after acquiring an additional 340,112 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in GlycoMimetics by 61.8% in the second quarter. Acadian Asset Management LLC now owns 534,753 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 204,227 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in GlycoMimetics by 483.5% during the second quarter. Renaissance Technologies LLC now owns 826,851 shares of the biotechnology company’s stock worth $233,000 after buying an additional 685,151 shares during the last quarter. Institutional investors own 75.19% of the company’s stock.
GlycoMimetics Company Profile
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
Further Reading
- Five stocks we like better than GlycoMimetics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- Dividend Capture Strategy: What You Need to Know
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.